A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors
- Registration Number
- NCT06300216
- Lead Sponsor
- Qilu Hospital of Shandong University
- Brief Summary
The aim of this multicenter, open-label, observational study is to evaluate the safety and efficacy of octreotide microspheres in the treatment of advanced neuroendocrine tumors in real clinical practice, especially to evaluate the treatment of octreotide microspheres in various subgroups of neuroendocrine tumor patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
- Sign an informed consent form and voluntarily participate in this study;
- Patients with unresectable or metastatic neuroendocrine tumors confirmed by histopathology. Patients with recurrence and progression after surgery or local treatment can also be included in the study;
- Age ≥ 18 years old;
- Treatment with octreotide microspheres.
Exclusion Criteria
- Confirmed pregnant or lactating women;
- Participating in any research with intervention measures outside of routine clinical practice;
- Other situations unsuitable for inclusion in the study determined by the researcher.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Octreotide microspheres standard dose monotherapy Octreotide microspheres -
- Primary Outcome Measures
Name Time Method Treatment Emergent Adverse Events up to 46 months Treatment emergent adverse events were recorded according to Common Terminology Criteria for Adverse Events (version 5.0) of the National Cancer Institute that participants received at least one dose of protocol treatment.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Qilu hospital of Shandong University
🇨🇳Jinan, Shandong, China